Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
201-220 of 1,743 trials

ZN-c3 for High-Grade Serous Ovarian Cancer

We are studying a new treatment called azenosertib for individuals with high-grade serous ovarian cancer. The trial aims to evaluate its safety and effectiveness, especially in patients with a specific genetic marker.

Ovarian, Fallopian Tube, and Peritoneal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Atrial Fibrillation: Stopping Anticoagulants After Heart Surgery

We are studying whether patients with atrial fibrillation can safely stop anticoagulant therapy after undergoing surgical left atrial appendage closure. This trial looks at the risks of stroke and bleeding in these patients.

Atrial Fibrillation>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine

Early Breast Cancer: Ribociclib with Endocrine Therapy

We are studying the effects of ribociclib combined with endocrine therapy in patients with HR-positive, HER2-negative early breast cancer. This trial aims to understand how well this treatment works and its safety.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Heart Failure Treatment: Carvedilol vs. Metoprolol

We are comparing two heart medications to see which one may better help patients with heart failure and reduced ejection fraction. This study involves patients who need beta-blocker treatment for their condition.

Heart Failure>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Advanced Thyroid and Head and Neck Cancer: [18F]AlF-PSMA-11 PET Study

We are investigating how well [18F]AlF-PSMA-11 PET detects cancer lesions in patients with advanced thyroid and head and neck carcinoma. This study compares its effectiveness to other imaging methods.

Head and Neck Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineOncologyOtolaryngology

Castration-Resistant Prostate Cancer: Lutetium [177Lu] VIPIVOTIDE TETRAXETAN

We are studying a new treatment for men with castration-resistant prostate cancer to see how well it works alone and with other medications. The goal is to evaluate its effects on prostate-specific antigen (PSA) levels and overall health.

Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)Standard MedicinesPartially RemoteOncology

Advanced Solid Tumors: ODM-212 Study

We are testing a new oral medication, ODM-212, in patients with advanced solid tumors to evaluate its safety and how well it may work. This study aims to find the best dose and understand its effects on tumor growth.

Neoplasms (Tumors)>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Multiple Myeloma: HUVR-CARTemis-1 T-Cell Therapy

We are studying a new T-cell therapy for patients with multiple myeloma who have relapsed after an allogeneic transplant. The trial aims to evaluate the safety and effectiveness of this treatment over time.

Multiple Myeloma Progression>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Gastrointestinal Stromal Tumors: Imatinib and Atezolizumab Study

We are investigating whether combining imatinib with atezolizumab helps patients with advanced GIST who have not responded to other treatments. The study aims to assess survival rates and quality of life improvements.

Unresectable Gastrointestinal Stromal Tumor (GIST)Metastatic Gastrointestinal Stromal TumorLocally Advanced Gastrointestinal Stromal Tumor (GIST)>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Cystic Fibrosis: Vanzacaftor/Tezacaftor/Deutivacaftor Therapy

We are studying a new combination therapy for cystic fibrosis in individuals aged one year and older. The trial aims to evaluate its long-term safety and effectiveness.

Cystic Fibrosis>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicinePulmonology

Colorectal Cancer: CC-3 Antibody Study

We are testing a new bispecific antibody for patients with colorectal cancer to see if it is safe and effective. This is the first time this treatment is being evaluated in humans.

Progressive Metastatic Solid Cancer>2 yearsSafety phase (I)Oncology

Limb Girdle Muscular Dystrophy 2E/R4: SRP-9003 Gene Therapy

We are studying a new gene therapy to see if it improves muscle function in people with Limb Girdle Muscular Dystrophy 2E/R4. The trial will evaluate its safety and effectiveness over time.

Limb-girdle Muscular Dystrophy Type 2E/R4>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Metastatic Breast Cancer: Elacestrant Combinations

We are evaluating the safety and effectiveness of Elacestrant in various combinations for patients with metastatic breast cancer. This study aims to find better treatment options for this condition.

Metastatic Breast Cancer>2 yearsSafety phase (I)Oncology

Metastatic Prostate Cancer: JNJ-78278343 Treatment Study

We are testing a new T-cell redirecting agent combined with other therapies for men with metastatic prostate cancer. The study aims to see if this combination can improve treatment results.

Metastatic Prostate Cancer>2 yearsSafety phase (I)OncologyUrology

Asymptomatic Heart Failure: TREASURE Trial

We are studying whether an ACE inhibitor can improve heart health in women with asymptomatic heart failure compared to usual care. The trial also looks at its effects on heart function, metabolic health, and quality of life.

Subclinical Heart Failure>2 yearsMonitoring phase (IV)Standard MedicinesCardiologyInternal Medicine

Mucopolysaccharidosis Type II: JR-141 Treatment Study

We are investigating the long-term effects of JR-141 on symptoms of Hunter Syndrome. This study will help us understand its safety and effectiveness for patients with this condition.

Mucopolysaccharidosis IIHunter Syndrome>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNeurologyPediatrics

Advanced Solid Tumors: RO7589831 and Pembrolizumab

We are testing a new treatment combining RO7589831 with Pembrolizumab for people with advanced solid tumors. This study aims to understand how effective this combination may be in managing their condition.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Sotorasib for Advanced Lung Cancer with KRAS G12C Mutation

We are studying whether sotorasib can help reduce tumor size in patients with advanced lung cancer who have other health conditions. The trial also looks at quality of life and safety during treatment.

KRAS G12C-Mutated Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineOncology

ANCA-Associated Vasculitis: Avacopan Study

We are testing the long-term safety and effectiveness of Avacopan for people with ANCA-associated vasculitis. The study will also look at how it affects remission and overall quality of life.

Anti-neutrophil Cytoplasmic Antibody Positive Vasculitis>2 yearsMonitoring phase (IV)Standard MedicinesCost ReimbursementInternal MedicineRheumatology

Prostate Cancer: Long-Term Safety of Lutetium (177Lu) Treatment

We are investigating the long-term safety of lutetium (177Lu) vipivotide tetraxetan in adults with prostate cancer. This study aims to identify potential risks and serious side effects over time.

Prostate Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology